LBF20208PG01: Difference between revisions

No edit summary
No edit summary
Line 6: Line 6:
|LipidBank=XPR1771
|LipidBank=XPR1771
|LipidMaps=LMFA03010101
|LipidMaps=LMFA03010101
|SysName=9a,15S-dihydroxy-11-oxo-prosta-5Z,12E-dien-1-oic acid
|SysName=9alpha,15S-dihydroxy-11-oxo-prosta-5Z,12E-dien-1-oic acid
|Common Name=&&d12-Prostaglandin D_2&&9a,15S-dihydroxy-11-oxo-prosta-5Z,12E-dien-1-oic acid&&
|Common Name=&&delta12-Prostaglandin D_2&&9alpha,15S-dihydroxy-11-oxo-prosta-5Z,12E-dien-1-oic acid&&
|Source=
|Source=
|Chemical Synthesis=
|Chemical Synthesis=

Revision as of 05:24, 20 January 2010

LipidBank Top
(トップ)
Fatty acid
(脂肪酸)
Glycerolipid
(グリセロ脂質)
Sphingolipid
(スフィンゴ脂質)
Journals
(雑誌一覧)
How to edit
(ページの書き方)


Upper classes: LB LBF



δ12-Prostaglandin D2
LBF20208PG01.png
Structural Information
9α,15S-dihydroxy-11-oxo-prosta-5Z,12E-dien-1-oic acid
  • δ12-Prostaglandin D2
  • 9α,15S-dihydroxy-11-oxo-prosta-5Z,12E-dien-1-oic acid
Formula C20H32O5
Exact Mass 352.224974134
Average Mass 352.46508
SMILES C(CC[C@H](O)CC=C([C@H]1CC=CCCCC(O)=O)C(C[C@@H]1O)=O)CC
Physicochemical Information
d12-PGD2 is catalyzed to d12-PGJ2, which has antimitotic and carcinogenic activities. Kato_T et al. Fukushima_M
Spectral Information
Mass Spectra
UV Spectra
IR Spectra
NMR Spectra
Other Spectra
Chromatograms
Reported Metabolites, References
Biospecies ID Compound Name Reference Comment
n.a. LBF20208PG01 See above. Fukushima_M 1990
n.a. LBF20208PG01 See above. Kato_T et al. 1986